Vertex Receives Positive Opinion from CHMP for Kalydeco in Patients 12 to 24 months wth Cystic Fibrosis

Vertex Receives Positive Opinion from CHMP for Kalydeco in Patients 12 to 24 months wth Cystic Fibrosis

Source: 
CP Wire
snippet: 

Vertex Pharmaceuticals (Europe) announced on 10/19/18 that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO®(ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.